Ten-year costs of cardiovascular disease in genetically verified familial hypercholesterolaemia compared with age- and sex-matched controls
Familial hypercholesterolaemia patients had about three times higher CVD-related hospital costs and more than 10 times higher pharmaceutical costs than age- and sex-matched controls during a 10-year follow-up. During the 10 years, costs for pharmaceuticals increased and costs for hospital decreased.
Authors
- Kjetil Retterstøl (ORCID: https://orcid.org/0000-0002-1309-7556)
- Jannicke Igland (ORCID: https://orcid.org/0000-0002-2289-0978)
- Martin P. Bogsrud (ORCID: https://orcid.org/0000-0002-2321-2490)
- Ivar Sønbø Kristiansen (ORCID: https://orcid.org/0000-0002-5389-6010)
- Torbjørn Fosen Wisløff (ORCID: https://orcid.org/0000-0002-7539-082X)
- Karianne Svendsen (ORCID: https://orcid.org/0000-0002-7628-0999)
- Liv Mundal
Institutions
- Oslo University Hospital (NO)
- Norwegian Institute of Public Health (NO)
- University of Southern Denmark (DK)
- Western Norway University of Applied Sciences (NO)
- OsloMet – Oslo Metropolitan University (NO)
- University of Oslo (NO)
- Akershus University Hospital (NO)
- Cancer Registry of Norway (NO)
- Western Norway University of Applied Sciences (NO)
- University of Bergen (NO)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2025-09-22
- DOI
- https://doi.org/10.1093/eurjpc/zwaf592
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Helse Sør-Øst RHF